Mirum Pharmaceuticals, Inc. Debt Securities, Available-for-sale, Current
Mirum Pharmaceuticals, Inc. (MIRM) had Debt Securities, Available-for-sale, Current of $107.56 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Current $107.56M.
- 2026-03-31: Debt Securities, Available-for-sale, Current $61.35M.
- 2025-12-31: Debt Securities, Available-for-sale, Current $86.64M.
- 2025-09-30: Debt Securities, Available-for-sale, Current $93.53M.
| Period end | Debt Securities, Available-for-sale, Current |
|---|---|
| 2026-06-30 | $107.56M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $61.35M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $86.64M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $93.53M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $76.43M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $65.85M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $57.81M 10-K · filed 2026-02-25 |
| 2024-09-30 | $61.48M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $45.13M 10-Q · filed 2024-08-07 |
| 2023-09-30 | $2.97M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $32.73M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $82.65M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $123.72M 10-K · filed 2024-03-15 |
| 2022-09-30 | $149.59M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $69.69M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $93.64M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $125.20M 10-K · filed 2023-03-08 |
| 2021-09-30 | $134.19M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $131.91M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $122.44M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $89.73M 10-K · filed 2022-03-09 |
| 2020-09-30 | $84.97M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $66.29M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $87.50M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $104.69M 10-K · filed 2021-03-09 |
| 2019-09-30 | $95.44M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $42.38M 10-Q · filed 2019-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |